75N91025C00024
Definitive Contract
Overview
Government Description
DIRECT TO PHASE II SBIR CONCEPT AWARD FOR NOVEL IONTOPHORETIC DRUG DELIVERY DEVICE FOR LOCAL AND EFFECTIVE TREATMENT OF ORAL CANCER
Awardee
Awarding / Funding Agency
Place of Performance
Cary, NC 27513 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Research Type
Small Business Innovation Research Program (SBIR) Phase II
Est. Average FTE
8
Related Opportunity
None
Continuity Biosciences was awarded
Definitive Contract 75N91025C00024 (75N910-25-C-00024)
worth up to $2,995,581
by National Cancer Institute
in September 2025.
The contract
has a duration of 2 years and
was awarded
with a Small Business Total set aside
with
NAICS 541715 and
PSC AN12
via direct negotiation acquisition procedures with 16 bids received.
Status
(Open)
Last Modified 8/22/25
Period of Performance
9/5/25
Start Date
9/4/27
Current End Date
9/4/27
Potential End Date
Obligations
$3.0M
Total Obligated
$3.0M
Current Award
$3.0M
Potential Award
Award Hierarchy
Definitive Contract
75N91025C00024
Subcontracts
Activity Timeline
People
Suggested agency contacts for 75N91025C00024
Competition
Number of Bidders
16
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
KTR8EE8DBFX5
Awardee CAGE
13F55
Agency Detail
Awarding Office
75N910 NIH NCI
Funding Office
75N910
Created By
hhsrturk
Last Modified By
hhsrturk
Approved By
hhsrturk
Legislative
Legislative Mandates
None Applicable
Performance District
NC-02
Senators
Thom Tillis
Ted Budd
Ted Budd
Representative
Deborah Ross
Modified: 8/22/25